⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534651 | 0.73 | — | — | |
| SCHEMBL5250090 | 0.73 | — | — | |
| SCHEMBL957350 | 0.73 | KDM4E (0.34) | — | |
| SCHEMBL1815329 | 0.60 | — | — | |
| SCHEMBL8404472 | 0.59 | — | — | |
| SCHEMBL2571045 | 0.57 | BRD4 (0.50) | — | |
| SCHEMBL2118787 | 0.57 | BRD4 (0.50) | — | |
| SCHEMBL16060757 | 0.57 | BRD4 (0.50) | — | |
| SCHEMBL15148291 | 0.57 | BRD4 (0.50) | — | |
| SCHEMBL23201571 | 0.56 | BRD4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | claimed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | claimed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | claimed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-09-27 | — | — | US | disclosed |
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9288869-B2 | Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-15 | — | — | US | disclosed |
| EP-2970265-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | disclosed |
| US-8575156-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| EP-2066647-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031594-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |